Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1677-1687

  Baron, Ralf ^a   Mayoral, Victor ^b   Leijon, Göran ^c   Binder, Andreas ^a   Steigerwald, Ilona ^d   Serpell, Michael ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d GRÜNENTHAL GMBH   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Diabetic polyneuropathy; Lidocaine plaster; Neuropathic pain; Post herpetic neuralgia; Pregabalin

Indexed keywords

LIDOCAINE; PREGABALIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHIC PAIN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PLASTER CAST; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ALGORITHMS; ANALGESICS; CASTS, SURGICAL; DIABETIC NEUROPATHIES; DRUG COMBINATIONS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; OSMOLAR CONCENTRATION; PAIN; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 67650495223     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903048078     Document Type: Article

References (49)

1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400
2. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51
3. Cruccu G, Anand P, Attal N, et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004;11:153-62
4. Belgrade MJ. Following the clues to neuropathic pain. Distribution and other leads reveal the cause and the treatment approach. Postgrad Med 1999;106:127-32, 135-40
5. Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007;57:S130-5
6. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008;22:417-42
7. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9
8. Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005; 6:317-25
9. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008;8:45-56
10. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008;9:660-74
11. Electronic Medicines Compendium. Versatis® 5% medicated plaster Summary of Product Characteristics, 21 October 2008. Available at: http://emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=19291 [Last accessed 17 November 2008]
12. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
13. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003; 43:111-17
14. Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008;9:S19-30
15. Argoff CE. Topical treatments for pain. Curr Pain Headache Rep 2004;8:261-7
16. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937-47
17. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40
18. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
19. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
20. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8
21. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007: CD004846
22. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(Suppl 2):S21-8
23. Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-18
24. Herrmann DN, Barbano RL, Hart-Gouleau S, et al. An openlabel study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005;6:379-84
25. Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83
26. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35
27. van Seventer R, Feister HA, Young Jr JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84
28. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
29. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60
30. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
31. Electronic Medicines Compendium. Lyrica® capsules Summary of Product characteristics, 9 January 2009. Available at: http:// emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinter Friendly.asp?documentid=14651 [Last accessed 22 January 2009]
32. Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 2007;9:36
33. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289-305
34. White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003; 4:321-30
35. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of 5% lidocaine (Lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Invest 2009;29:231-41
36. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
37. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-9
38. Electronic Medicines Compendium. Lyrica capsules SPC, 2009. Available at: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp? documentid=14651 [Last accessed 13 March 2009].
39. Galer BS, Jensen MP, Ma T, et al. The lidocaine (lignocaine) patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301
40. Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408
41. Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009;25:1295-305
42. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804-13
43. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352: 1324-34
44. Khoromi S, Cui L, Nackers L, et al. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;130:66-75
45. Silver M, Blum D, Grainger J, et al. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manag 2007;34: 446-54
46. Baron R, Binder A, Boesl I, et al. Long-term efficacy, safety and quality of life with lidocaine 5% medicated plaster in postherpetic neuralgia. Pain in Europe V 5 th Congress of the European Federation of IASP chapters (EFIC) Istanbul, Turkey, September 13-16, 2006; Abstract 787
47. Hans G, Baron R, Binder A, et al. Long-term efficacy and tolerability of a 5% lidocaine-medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. IASP abstract 2008.
48. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163:628
49. Argoff CE. Lidocaine patch 5% and the management of chronic pain. South Med J 2002;95:781